JTO Clinical and Research Reports
Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1
By Marina Chiara Garassino, MD, Ana Baramidze, MD, Saadettin Kilickap, MD and 7 others.
Abstract
Introduction
Treatment options are limited for patients with advanced NSCLC who progress on anti–programmed cell death-ligand 1 (anti–PD-L1) monotherapy. Second-line platinum-based chemotherapy provides a short progression-free survival (PFS) of approximately 3 to 4 months. The EMPOWER-Lung 1 study allowed continued cemiplimab with the addition of platinum-based chemotherapy after progression as a second-line treatment (cemiplimab beyond progression [CBP]). Here, we report long-term outcomes in this setting.
